Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 30.20% is 21% below its 5-year average of 38.35%, around the middle of its 5-year range (-60.54%–86.19%).
29.96% below its 12-month average of 43.12%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 26.20%.
EBITDA MARGIN
30.20%
EBITDA MARGIN AVG TTM
43.12%
EBITDA MARGIN AVG 3Y
32.59%
EBITDA MARGIN AVG 5Y
38.35%
EBITDA MARGIN AVG 10Y
42.64%
EBITDA MARGIN AVG 15Y
38.99%
EBITDA MARGIN AVG 20Y
25.85%
CURRENT VS TTM AVG
-29.96%
CURRENT VS 3Y AVG
-7.32%
CURRENT VS 5Y AVG
-21.26%
CURRENT VS 10Y AVG
-29.17%
CURRENT VS 15Y AVG
-22.55%
CURRENT VS 20Y AVG
+16.81%
Ligand Pharmaceuticals Incorporated
Market Cap
$5.93B
EBITDA Margin
30.20%
TTM Avg
43.12%
3Y Avg
32.59%
5Y Avg
38.35%
Market Cap
$5.95B
EBITDA Margin
-139.44%
TTM Avg
-176.89%
3Y Avg
-12100.88%
5Y Avg
-12100.88%
Market Cap
$6.06B
EBITDA Margin
-256.72%
TTM Avg
-936.95%
3Y Avg
-3212.66%
5Y Avg
-4222.05%
Market Cap
$5.74B
EBITDA Margin
11.63%
TTM Avg
0.63%
3Y Avg
-0.42%
5Y Avg
-80.39%
Market Cap
$5.71B
EBITDA Margin
-4686.36%
TTM Avg
-7375.40%
3Y Avg
-15092.23%
5Y Avg
-12098.10%
Market Cap
$6.29B
EBITDA Margin
-100.49%
TTM Avg
-151.66%
3Y Avg
-322.50%
5Y Avg
-1329.03%
Market Cap
$5.51B
EBITDA Margin
1.58%
TTM Avg
-0.29%
3Y Avg
0.97%
5Y Avg
0.97%
Market Cap
$6.51B
EBITDA Margin
24.71%
TTM Avg
29.36%
3Y Avg
25.12%
5Y Avg
17.03%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | $5.93B | 30.20% | 43.12% | 32.59% | 38.35% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | -139.44% | -176.89% | -12100.88% | -12100.88% |
| GRAIL Inc. (GRAL)vs › | $6.06B | -256.72% | -936.95% | -3212.66% | -4222.05% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 11.63% | 0.63% | -0.42% | -80.39% |
| CG Oncology Inc. (CGON)vs › | $5.71B | -4686.36% | -7375.40% | -15092.23% | -12098.10% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.29B | -100.49% | -151.66% | -322.50% | -1329.03% |
| RadNet, Inc. (RDNT)vs › | $5.54B | 11.91% | 12.58% | 14.79% | 16.03% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.51B | 1.58% | -0.29% | 0.97% | 0.97% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 24.71% | 29.36% | 25.12% | 17.03% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.51B | 21.42% | 19.40% | 15.87% | 16.39% |
Gross Margin
98.6%
EBITDA Margin
30.2%
Operating Margin
17.6%
Net Margin
67.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 26.20% |
| 2026-03-31 | 49.46% |
| 2025-12-31 | 49.72% |
| 2025-09-30 | 54.59% |
| 2025-06-30 | 35.62% |
| 2025-03-31 | -60.54% |
| 2024-12-31 | -2.36% |
| 2024-09-30 | 23.43% |
| 2024-06-30 | -24.67% |
| 2024-03-31 | 37.94% |
| 2023-12-31 | 19.80% |
| 2023-09-30 | 35.56% |
| 2023-06-30 | 28.49% |
| 2023-03-31 | 54.05% |
| 2022-12-31 | 86.19% |
| 2022-09-30 | 43.64% |
| 2022-06-30 | 43.39% |
| 2022-03-31 | 43.21% |
| 2021-12-31 | 35.44% |
| 2021-09-30 | 43.68% |
| 2021-06-30 | 68.53% |
| 2021-03-31 | 32.29% |
| 2020-12-31 | 34.33% |
| 2020-09-30 | 19.82% |
| 2020-06-30 | 27.33% |
| 2020-03-31 | 30.66% |
| 2019-12-31 | 43.91% |
| 2019-09-30 | 13.65% |
| 2019-06-30 | 10.98% |
| 2019-03-31 | 1915.24% |
| 2018-12-31 | 61.47% |
| 2018-09-30 | 63.01% |
| 2018-06-30 | 81.61% |
| 2018-03-31 | 71.31% |
| 2017-12-31 | 64.09% |
| 2017-09-30 | 55.46% |
| 2017-06-30 | 56.16% |
| 2017-03-31 | 45.08% |
| 2016-12-31 | 57.84% |
| 2016-09-30 | 37.80% |
| 2016-06-30 | 36.83% |
| 2016-03-31 | 59.43% |
| 2015-12-31 | 55.22% |
| 2015-09-30 | 52.21% |
| 2015-06-30 | 27.21% |
| 2015-03-31 | 27.39% |
| 2014-12-31 | 44.77% |
| 2014-09-30 | 28.00% |
| 2014-06-30 | 19.11% |
| 2014-03-31 | 36.14% |
| 2013-12-31 | 48.05% |
| 2013-09-30 | 28.74% |
| 2013-06-30 | 22.79% |
| 2013-03-31 | 39.50% |
| 2012-12-31 | 37.70% |
| 2012-09-30 | -10.73% |
| 2012-06-30 | -18.60% |
| 2012-03-31 | -1.54% |
| 2011-12-31 | 49.62% |
| 2011-09-30 | -46.14% |
| 2011-06-30 | -0.33% |
| 2011-03-31 | -42.45% |
| 2010-12-31 | -148.91% |
| 2010-09-30 | -192.34% |
| 2010-06-30 | -50.10% |
| 2010-03-31 | -55.07% |
| 2009-09-30 | 34.57% |
| 2009-06-30 | -49.05% |
| 2009-03-31 | -66.92% |
| 2008-12-31 | -590.45% |
| 2008-09-30 | -97.31% |
| 2007-12-31 | -133.07% |
| 2007-09-30 | -151.94% |
| 2007-06-30 | -952.34% |
| 2007-03-31 | -11969.79% |
| 2006-12-31 | 22.22% |
| 2006-09-30 | -29.68% |
| 2006-06-30 | -13.12% |
| 2006-03-31 | -259.78% |
| 2005-12-31 | 8.35% |
| 2005-09-30 | 2.89% |
| 2005-06-30 | -3.89% |
| 2005-03-31 | -30.58% |
| 2004-12-31 | -21.68% |
| 2004-09-30 | -0.03% |
| 2004-06-30 | -18.82% |
| 2004-03-31 | -17.63% |
| 2003-12-31 | 24.70% |
| 2003-09-30 | -14.91% |
| 2003-06-30 | -18.99% |
| 2003-03-31 | -38.65% |
| 2002-12-31 | -0.68% |
| 2002-09-30 | -19.84% |
